Vaccine Adjuvants Companies

GSK Received FDA approval for Arexvy, a respiratory syncytial virus vaccine adjuvanted for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older.Partnered with Affinivax in August 2022, acquiring their lead adjuvant candidate AFX27 and bolstering their vaccine adjuvant portfolio.

Novavax Collaborated with the Gates Foundation Offshoot in June 2023 to develop new malaria and tuberculosis vaccines utilizing their Matrix-M™ adjuvant platform.Entered into a Phase 3 clinical trial for their NVX-CoV2373 COVID-19 booster vaccine incorporating their saponin-based adjuvant Matrix-M.

Dynavax Technologies (US) Achieved positive preliminary results from a Phase 2 clinical trial evaluating CpG 1018 as an adjuvant for a plague vaccine in October 2023.Secured a new manufacturing partnership with Lonza in November 2023 to expand production capacity for their CpG 1018 adjuvant.

Croda International Entered into a strategic partnership with Amyris (US) and Botanical Solutions Inc. in May 2023 to accelerate production of their QS-21 adjuvant.Announced plans to expand their manufacturing facilities for QS-21 in Asia and Europe to meet the growing demand for innovative vaccine adjuvants.

Seqirus (UK) Partnered with the University of Oxford in November 2023 to develop a new vaccine against Nipah virus using their MF59 adjuvant platform.Focused on expanding their pipeline of adjuvanted vaccines for various infectious diseases, including influenza and Chikungunya.

List of Vaccine Adjuvants Key Companies in the Market

• Adjuvatis


• GlaxoSmithKline PLC


• Croda International PLC


• Merck KGaA


• TjKaiwei


• OZ Biosciences


• Brenntag Biosector


• MVP Laboratories


• Zhuoyue


• Aphios


• Novavax Inc.